

Francesco Costa, MSc, PhD

Education

- March 2011 **M.Sc., Healthcare Management**
SDA Bocconi, School of Management, Milano, Italy
- January 2010 **Ph.D., Morphological Sciences**
Università degli Studi di Milano, School of Medicine, Milano, Italy
Dissertation Title: "*Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model*"
- October 2006 **M.Sc., Medical Biotechnology**
Università degli Studi di Milano, School of Medicine, Milano, Italy
Dissertation Title: "*Ochratoxin A-induced Renal Cortex Fibrosis and Epithelial-to-Mesenchymal Transition: Molecular Mechanism of Ochratoxin A-Injury and Potential Effects of Red Wine*"
Final score: 103/110

Work Experience

September 2012 – Present

CERGAS-SDA Bocconi

Research Fellow: Health Economics & HTA area; Health Policy area

- Monitoring of national and international pharmaceutical policy
- Pharmaceutical market analysis
- Forecasting of Italian pharmaceutical market
- Pharmaceutical budget analysis
- Budget impact analysis
- Health Economics
- HTA
- Monitoring of national and international policy on Medical Devices
- Teaching activity of pharmaceutical policy (Master in Healthcare Management-MiMS SDA Bocconi; Open market courses of HTA and Market Access SDA Bocconi)

July 2011 - January 2012

Dompè Pharmaceutical Italia

Business Development intern

- Analysis for licensing in/out activity
- Business Intelligence
- Pharmaceutical market analysis

December 2010 - June 2011

AstraZeneca Italia S.p.A

Market Access, Pricing and Health Economic intern

- Drafting of value dossier
- Pharmaceutical pricing analysis

November. 2006- October 2009

Università degli Studi di Milano, Human Morphology Department. Milano
Research Associate

Publication

- *La Rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane.* Mecosan 2016, 98.
- *Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento.* Rapporto OASI 2016. Egea
- *La spesa sanitaria: composizione ed evoluzione.* Rapporto OASI 2016. Egea
- *Il confronto dei sistemi sanitari in una prospettiva internazionale.* Rapporto OASI 2016. Egea
- *Organizzazione e gestione delle sperimentazioni cliniche.* A cura di: Marianna Cavazza; Francesco Costa e Claudio Jommi. 2016, Egea
- *La spesa sanitaria: composizione ed evoluzione.* Rapporto OASI 2015. Egea
- *Il confronto dei sistemi sanitari in una prospettiva internazionale.* Rapporto OASI 2015. Egea
- *I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia.* Rapporto OASI 2014. Egea
- *La ricerca clinica in nove ospedali italiani: organizzazione e analisi di percezione.* Rapporto OASI 2014. Egea
- *I prezzi a ricavo industria dei farmaci rimborsabili: l'Italia a confronto con i principali paesi Ue.* Politiche Sanitarie 2013 14 (2) 55-66
- *Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro.* Anticancer Drugs 2011 Sep 22 (8) 749-62;
- *Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression.* Pancreatology 2010 10 (5) 545-52.
- *Effects of aging and cyclosporin A on collagen turnover in human gingiva.* Open Dent J. 2009 Nov 5 (3):219-26.
- *Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model* Oncol Rep. 2009; 22: 1349-56.
- *Sperm protein 17 is expressed in the sperm fibrous sheath.* J Transl Med. 2009, 15: 7-61.
- *Expression profiling genes involved in collagen turnover in tendons from cerebral palsy patients.* Connect Tissue Res. 2009, 50 (3): 203- 208.
- *A therapeutic dose of FK506 does not affect collagen turnover pathways in healthy human gingival fibroblasts.* Transplant Proc. 2008, 40: 1419-1424.
- *Ukrain modulates glial fibrillary acid protein, but not connexin 43 expression, and induces apoptosis in human cultured glioblastoma cells.* Anti-Cancer Drugs 2007, 18 (6): 669-676.
- *Early cytotoxic effects of ochratoxin A in rat liver: A morphological, biochemical and molecular study.* Toxicology 2006, 225: 214-22.
- *Ochratoxin A-induced Renal Cortex Fibrosis and Epithelial-to-Mesenchymal Transition: Molecular Mechanism of Ochratoxin A-Injury and Potential Effects of Red Wine.* Molecular Medicine 2005,11: 39-38.

Additional Informations

Languages: Italian (native), English (Proficient user)

Abroad experience: August 2005 Texas Tech University Lubbock Texas USA: Visiting Researcher.